209 related articles for article (PubMed ID: 28205056)
1. Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Adv Ther; 2017 Mar; 34(3):753-764. PubMed ID: 28205056
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
Adena MA; Hamann G; Sindone AP
Heart Lung Circ; 2019 Mar; 28(3):414-422. PubMed ID: 29449079
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
5. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Zugck C; Martinka P; Stöckl G
Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
[TBL] [Abstract][Full Text] [Related]
7. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
8. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27153871
[TBL] [Abstract][Full Text] [Related]
10. Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
Zachariah D; Stevens D; Sidorowicz G; Spooner C; Rowell N; Taylor J; Kay R; Salek MS; Kalra PR;
Int J Cardiol; 2017 Dec; 249():313-318. PubMed ID: 29121732
[TBL] [Abstract][Full Text] [Related]
11. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
[TBL] [Abstract][Full Text] [Related]
13. Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure.
Mert KU; Dural M; Mert GÖ; Iskenderov K; Özen A
Aging Male; 2018 Jun; 21(2):93-98. PubMed ID: 28844168
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
Norrlid H; Dahm P; Tennvall GR
Scand J Pain; 2015 Jan; 6(1):24-30. PubMed ID: 29911578
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D.
Huang R; Rao H; Shang J; Chen H; Li J; Xie Q; Gao Z; Wang L; Wei J; Jiang J; Sun J; Jiang J; Wei L
Health Qual Life Outcomes; 2018 Jun; 16(1):124. PubMed ID: 29903024
[TBL] [Abstract][Full Text] [Related]
18. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
19. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
